The data collected in this current study have shown that NLRP3 inhibition with OLT1177® has a potential therapeutic value in preserving contractile reserve/β-adrenergic responsiveness, by way of preventing the significant desensitization and/or downregulation of the β-adrenergic receptors responsible for impairing the contractile reserve, a distinctive feature of cardiomyopathy and HF [34]. The gene discussed is NLRP3; the disease is cardiomyopathy.